サブメニュー

発表論文一覧

No 試験名 雑誌 論文名 執筆者
2023年度(2023年4月~)発表論文
1 RAMNITA The Oncologist
2023 Jun; 28(6): 551–e454

Ramucirumab plus docetaxel for non–small cell lung cancer patients with brain metastases: A multicenter, open-label single-arm phase II trial 京都府立医科大学
谷村 恵子
2 TCOG_LC1901
(UNICORN)
Journal of Clinical Oncology
2023; 41: 9045-9045.

Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study.
Meeting Abstract 2023 ASCO Annual Meeting I
国立がんセンター
中央病院
大熊 裕介
3 SPIRAL-DACO Cancer Medicine
Prophylactic treatment of dacomitinib-induced skin toxicities in EGFR-mutated non–small-cell lung cancer: a multicenter, phase II trial 京都府立医科大学
岩破 將博
4 SPIRAL-3D Therapeutic Advances in Medical Oncology
2023;15:1-8

Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study) 京都府立医科大学
河内 勇人
5 KYUCOG-1401A Endocr Relat Cancer
2023 Jun 1;30(7):e230044.

Genome-wide association studies identified genetic polymorphisms associated with prognosis in patients undergoing primary androgen deprivation therapy for advanced prostate cancer: KYUCOG-1401-A study 九州大学
塩田 真己
6 SNiP-RCC International Journal of Urology
2023 Sep;30(9):788-796.

Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study 九州大学
Leandro Blas
7 SPIRAL-BRAIN Translational Lung Cancer Research
2023 Aug 30;12(8):1802-1806.

A protocol of a single arm, prospective, open-label, multicenter, phase II study of ramucirumab and erlotinib in treatment-naïve non-small cell lung cancer patients with EGFR mutation and brain
metastases (SPIRAL-BRAIN study)
京都府立医科大学
澤田 凌
8 TORG1938
(EPONA)
Future Oncology
2023 Jul;19(22):1515-1521.

Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study) 国立がんセンター
中央病院
大熊 裕介
9 LOGIK1603 JTO Clinical and Research Reports
A Phase II Single-Arm Study of Osimertinib for Radiotherapy-Naive CNS Metastasis Non-Small Cell Lung Cancer: Results for the First-line cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L) 静岡県立
静岡がんセンター
和久田 一茂
10 SPIRAL-RT European Journal of Cancer
A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: the SPIRAL-RT study 京都府立医科大学
山田 忠明
11 TCOG_LC1901
(UNICORN)
JAMA Oncology
2024 Jan 1;10(1):43-51.

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial 国立がんセンター
中央病院
大熊 裕介
12 KYUCOG-1401 International Journal of Urology
GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401 原三信病院
横溝 晃
13 SPADE European Journal of Obstetrics & Gynecology and Reproductive Biology
The effects of dienogest and combined oral contraceptives on protein S-specific activity in endometriosis patients 九州大学
横田 奈津子
2022年度(2022年4月~2023年3月)発表論文
1 LOGIK1303 JMA Journal
2022; 5: 334–40.

Efficacy and Safety of Sitafloxacin in Treating Low-risk Febrile Neutropenia in Patients with Lung Cancer 福岡大学
温 麟太郎
2 福岡和白病院・浅間総合病院
共同研究
Current Medical Research and Opinion
2022 Sep;38(9):1567-1578

Effects of pericapsular soft tissue and realignment exercises for patients with osteoarthritis of the hip and Harris Hip Score below 60 points 和白病院
林 和生
3 W-JHS MDS01 International Journal of Hematology
ASXL1 mutations with serum EPO levels predict a poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial 近畿大学
森田 泰慶
4 LOGIK1605 Thoracic Cancer
2022;13:2499–506

Phase II study of S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Results of the LOGIK1605/JART-1501 study 長崎県島原病院
福田 実
5 LOGIK2002 BMC Cancer
(2022) 22:964

Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial 九州大学
白石 祥理
6 SPIRAL-0 The Oncologist
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study 宇治徳洲会病院
千原 佑介
7 SPIRAL-II JTO Clinical and Research Reports
Osimertinib and bevacizumab co-treatment for untreated epidermal growth factor receptor–mutated non-small-cell lung cancer with malignant pleural and/or pericardial effusion (SPIRAL II): A single-arm, open-label, phase II clinical trial 湘南藤沢徳洲会病院
日比野 真
8 LOGIK2003 Thoracic Cancer
2022;1–3

Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003) 久留米大学
石井 秀宣
9 LOGIK2001 Cancer Management and Research
2022:14 3449–3453

Forthcoming Phase II Study of Durvalumab (MEDI4736) plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases 九州大学
白石 祥理
10 B-PAD Clin Exp Allergy
2023 Feb;53(2):233-238.

Exploring biomarkers to predict clinical improvement of Atopic Dermatitis in patients treated with dupilumab (B-PAD study) 九州大学
中原 剛士
11 SNiP-RCC Cancer Immunology, Immunotherapy
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial 九州大学
塩田 真己
2021年度(2021年4月~2022年3月)発表論文
1 LOGIK1607 JTO Clinical and Research Reports
High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib 大分大学
小副川 敦
2 LOGIK0902 ESMO Open
2021 Aug;6(4):100191
Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study 岡山大学
堀田 勝幸
3 LOGIK1603 Journal of Thoracic Oncology A phase II study of osimertinib for radiotherapy-naïve CNS metastasis from non-small cell lung cancer: Results for the T790M cohort of the OCEAN study (LOGIK1603/WJOG9116L) 長崎大学
山口 博之
4 LOGIK2004 Cancer Management and Research
2021;13:8489-93
Phase II Study of Nivolumab plus Ipilimumab with Platinum-Based Chemotherapy for Treatment-Naïve Advanced Non–Small Cell Lung Cancer with Untreated Brain Metastases: NIke Trial (LOGiK2004) 北九州医療センター
土屋(河野) 裕子
5 TCOG_LC1901
(UNICORN)
Future Oncology
VOL. 18, NO. 5
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901) 国立がんセンター
中央病院
大熊 裕介
6 LOGIK1601 International Journal of Clinical Oncology A prospective observational study of postoperative adjuvant chemotherapy for non‑small cell lung cancer in elderly patients (≥ 75 years) 別府医療センター
矢野 篤次郎
2020年度(2020年4月~2021年3月)発表論文
1 LOGIK1101 The Oncologist
2020;25:1-10
Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study 九州がんセンター
野崎 要
2 LOGIK0602 BMC Cancer
2020 4;20(1):1192
A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study 長崎大学
土屋 智史
3 LOGIK 1603 /WJOG 9116L BMC Cancer
(プロトコール論文)
2020 1;20(1):370
A Phase II Study of Osimertinib for Patients with Radiotherapy-naive CNS Metastasis of Non-Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the OCEAN Study 長崎大学
福田 実
4 LOGIK1604 Eur J Cancer .
2021;149:14-22
Osimertinib Versus Osimertinib Plus Chemotherapy for Non-Small Cell Lung Cancer with EGFR (T790M)-Associated Resistance to Initial EGFR Inhibitor Treatment: An Open-Label, Randomized Phase 2 Clinical Trial 九州大学
田中 謙太郎
5 SPIRAL-Study J. Clin. Med.
2020 5;9(6):1762
Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment 福岡大学
中尾 明
6 FRABR_ABT02 Immunological Medicine
2020 29;1-5.
Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production 九州大学
山田 久方
7 CONTACT Neurourology and Urodynamics
2020; 39: 804-12.
A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study) 獨協医科大学病院
山西 友則
8 GAP Lower Urinary Tract Symptoms.
2021; 13(2):224-229.
Prevalence of xerostomia with or without overactive bladder symptoms 新潟大学
伊藤 加代子
9 QUATRO Study BMC Ophthalmology
2021 21:58
Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study 九州大学
大島 裕司
10 DIrecT Study Urologia Internationalis
2021 9;1-9
Triple therapy with tamsulosin, dutasteride, and imidafenacin for benign prostatic hyperplasia in patients with overactive bladder symptoms refractory to tamsulosin: Subgroup analyses of DIrecT study 獨協医科大学病院
山西 友則
11 洗浄剤 Advances in Wound Care
2021 Mar 30.
Effects of hand hygiene using 4% chlorhexidine gluconate or natural soap during hand rubbing followed by alcohol-based 1% chlorhexidine gluconate sanitizer lotion in the operating room 福岡大学
秋田 定伯